MLTX MoonLake Immunotherapeutics

$13.40

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 11/18/2025

About MoonLake Immunotherapeutics

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1821586
Address
C/O CORMORANT ASSET MANAGEMENT, LLP, 200 CLARENDON STREET FL 52, BOSTON, MA, US
Valuation
Market Cap
$2.43B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
5.43
Performance
EPS
$-1.89
Dividend Yield
Profit Margin
0.00%
ROE
-25.10%
Technicals
50D MA
$39.63
200D MA
$46.40
52W High
$58.26
52W Low
$31.42
Fundamentals
Shares Outstanding
63M
Target Price
$77.77
Beta
1.31

MLTX EPS Estimates vs Actual

Estimated
Actual

MLTX News & Sentiment

Nov 18, 2025 • Motley Fool NEUTRAL
5AM Venture Bails on MoonLake After a Brutal Year: Here's What Stands Out
A major biotech investor just walked away from MoonLake after a rough year for the stock. Here's what that move signals-and what long-term investors should keep an eye on next.
Nov 17, 2025 • Benzinga SOMEWHAT-BEARISH
Bragar Eagel & Squire, P.C. Reminds Stockholders of aTyr, Marex, Cepton, and MoonLake to Contact the Firm About their Rights Before Upcoming Deadlines - aTyr Pharma ( NASDAQ:ATYR )
NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of aTyr Pharma, Inc. ( NASDAQ:ATYR ) , Marex Group PLC ( NASDAQ:MRX ) , Cepton, Inc. ...
Nov 17, 2025 • Benzinga NEUTRAL
MoonLake Immunotherapeutics Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before December 15, 2025 to Discuss Your Rights - MLTX - MoonLake ( NASDAQ:MLTX )
NEW YORK, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics ( "MoonLake" or the "Company" ) ( NASDAQ:MLTX ) of a class action securities lawsuit.
Nov 17, 2025 • Benzinga NEUTRAL
MLTX INVESTOR ALERT: MoonLake Immunotherapeutics ( MLTX ) Faces Securities Class Action After Company Reported Disastrous Phase 3 Trial Data For Sole Drug Candidate - Hagens Berman - MoonLake ( NASDAQ:MLTX )
SAN FRANCISCO, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- A securities class action, styled Bridgewood v.
Nov 14, 2025 • Benzinga NEUTRAL
DEADLINE ALERT for MLTX, BAX, and JHX: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - Baxter Intl ( NYSE:BAX ) , James Hardie Industries ( NYSE:JHX )
LOS ANGELES, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Nov 13, 2025 • Benzinga SOMEWHAT-BULLISH
ROSEN, LEADING TRIAL ATTORNEYS, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - MLTX - MoonLake ( NASDAQ:MLTX )
NEW YORK, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics ( NASDAQ:MLTX ) between March 10, 2024 and September 29, 2025, both dates inclusive ( the "Class Period" ) , of the important ...
Sentiment Snapshot

Average Sentiment Score:

0.068
50 articles with scored sentiment

Overall Sentiment:

Neutral

MLTX Reported Earnings

Aug 05, 2025
Jun 30, 2025 (Pre market)
-0.15 Surprise
  • Reported EPS: $-0.87
  • Estimate: $-0.72
  • Whisper:
  • Surprise %: -20.8%
May 12, 2025
Mar 31, 2025 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.63
  • Estimate: $-0.74
  • Whisper:
  • Surprise %: 14.3%
Feb 26, 2025
Dec 31, 2024 (Pre market)
-0.13 Surprise
  • Reported EPS: $-0.72
  • Estimate: $-0.59
  • Whisper:
  • Surprise %: -21.5%
Nov 07, 2024
Sep 30, 2024 (Pre market)
-0.12 Surprise
  • Reported EPS: $-0.56
  • Estimate: $-0.44
  • Whisper:
  • Surprise %: -27.3%
Aug 07, 2024
Jun 30, 2024 (Pre market)
-0.11 Surprise
  • Reported EPS: $-0.39
  • Estimate: $-0.28
  • Whisper:
  • Surprise %: -39.3%
May 07, 2024
Mar 31, 2024 (Pre market)
-0.03 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.19
  • Whisper:
  • Surprise %: -15.8%
Feb 29, 2024
Dec 31, 2023 (Pre market)
0.11 Surprise
  • Reported EPS: $-0.12
  • Estimate: $-0.23
  • Whisper:
  • Surprise %: 47.8%
Nov 14, 2023
Sep 30, 2023 (Pre market)
0.05 Surprise
  • Reported EPS: $-0.18
  • Estimate: $-0.23
  • Whisper:
  • Surprise %: 21.7%
Aug 10, 2023
Jun 30, 2023 (Pre market)
0.04 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.27
  • Whisper:
  • Surprise %: 14.8%

Financials